Kostas Stamatopoulos Selected Research

Complementarity Determining Regions (Complementarity Determining Region)

1/2021	Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
1/2019	Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations.
1/2013	Stereotyped B cell receptors in B cell leukemias and lymphomas.
10/2012	Partial versus productive immunoglobulin heavy locus rearrangements in chronic lymphocytic leukemia: implications for B-cell receptor stereotypy.
12/2010	Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors.
1/2007	Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kostas Stamatopoulos Research Topics

Disease

73	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2022 - 01/2005
28	Neoplasms (Cancer) 01/2022 - 07/2004
13	Lymphoma (Lymphomas) 01/2022 - 07/2004
8	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 01/2013
7	Disease Progression 11/2020 - 05/2008
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 06/2015 - 09/2011
6	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 10/2006
5	Lymphocytosis 01/2021 - 07/2009
3	Leukemia 01/2021 - 01/2013
3	Neutropenia 12/2017 - 12/2010
2	COVID-19 12/2021 - 01/2020
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 11/2020 - 10/2019
2	Residual Neoplasm 01/2019 - 01/2019
2	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 12/2017 - 03/2014
2	Large Granular Lymphocytic Leukemia 08/2014 - 01/2007
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2012 - 09/2010
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 09/2008 - 12/2002
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2003 - 03/2003
1	Hodgkin Disease (Hodgkin's Disease) 01/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2021
1	Trisomy (Trisomies) 12/2020
1	Pain (Aches) 11/2020
1	Thrombotic Microangiopathies 04/2020
1	Vaginal Diseases 10/2019
1	Inflammation (Inflammations) 10/2017
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/2017
1	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 03/2017
1	Blister (Bulla) 11/2014
1	Felty Syndrome (Syndrome, Felty's) 08/2014
1	Rheumatoid Arthritis 08/2014
1	Genetic Predisposition to Disease (Genetic Predisposition) 08/2014
1	Gastritis 03/2014
1	Bacterial Infections (Bacterial Infection) 12/2013

Drug/Important Bio-Agent (IBA)

50	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 07/2004
29	AntigensIBA 01/2021 - 07/2004
13	Biological ProductsIBA 01/2021 - 03/2003
6	EpitopesIBA 01/2021 - 01/2013
6	Complementarity Determining Regions (Complementarity Determining Region)IBA 01/2021 - 01/2007
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 12/2010
6	Rituximab (Mabthera)FDA Link 12/2019 - 08/2003
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2005
5	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019 - 11/2011
5	Antigen Receptors (Antigen Receptor)IBA 12/2017 - 03/2003
4	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 12/2017 - 12/2002
3	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2019
3	ibrutinibIBA 01/2020 - 05/2018
3	IgKIBA 01/2019 - 01/2005
3	Proteins (Proteins, Gene)FDA Link 11/2018 - 05/2013
3	Immunoglobulin G (IgG)IBA 01/2014 - 03/2008
2	Oxygen (Dioxygen)IBA 12/2021 - 01/2020
2	ChromatinIBA 12/2020 - 12/2013
2	fludarabineIBA 12/2019 - 02/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2019 - 02/2016
2	AntibodiesIBA 03/2017 - 11/2014
2	Messenger RNA (mRNA)IBA 06/2015 - 12/2003
2	Cytidine DeaminaseIBA 06/2015 - 04/2010
2	Immunoglobulin M (IgM)IBA 11/2014 - 01/2014
2	MicroRNAs (MicroRNA)IBA 10/2014 - 05/2013
2	Immunoglobulin D (IgD)IBA 01/2014 - 01/2008
2	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2009 - 11/2005
2	Transferrin Receptors (Transferrin Receptor)IBA 09/2008 - 12/2003
1	Complement System Proteins (Complement)IBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	Genetic Markers (Genetic Marker)IBA 01/2022
1	Vitamin D FDA LinkGeneric 01/2021
1	Calcitriol (Calcijex)FDA LinkGeneric 01/2021
1	Calcitriol Receptors (Calcitriol Receptor)IBA 01/2021
1	Stem Cell FactorIBA 01/2021
1	ribosomal protein S15IBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	LigandsIBA 01/2021
1	ParaffinIBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	CytokinesIBA 01/2021
1	ChemokinesIBA 01/2021
1	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 01/2021
1	3- (5- amino- 2- methyl- 4- oxoquinazolin- 3(4H)- yl)piperidine- 2,6- dioneIBA 01/2021
1	idelalisibIBA 05/2018
1	CalreticulinIBA 10/2017
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 10/2017
1	CarbohydratesIBA 03/2017
1	Cyclin D3IBA 01/2017
1	Histone MethyltransferasesIBA 06/2016
1	ofatumumab FDA Link 04/2015
1	AutoantigensIBA 11/2014
1	LDL Lipoproteins (beta Lipoproteins)IBA 11/2014
1	To autoantigenIBA 11/2014
1	alpha-beta T-Cell Antigen Receptors (T-Cell Receptor alpha-Chain)IBA 08/2014
1	HLA-DRB1*04 antigenIBA 08/2014
1	Enhancer of Zeste Homolog 2 ProteinIBA 05/2013

Therapy/Procedure

9	Therapeutics 01/2022 - 05/2012
3	Immunotherapy 01/2022 - 01/2021
3	Palliative Care (Palliative Therapy) 11/2021 - 06/2020
1	Precision Medicine 01/2022
1	Aftercare (After-Treatment) 01/2022
1	Cell Transplantation 04/2020
1	Critical Care (Surgical Intensive Care) 01/2020
1	Secondary Prevention 10/2019